prikaz prve stranice dokumenta Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
  Preuzmi
PDF 121.49 KB
Znanstveni rad - Izvorni znanstveni rad
Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
Biochemia Medica, 30 (2020), 1; 74-82. https://doi.org/10.11613/BM.2020.010702
Margetić, Sandra; Ćelap, Ivana; Delić Brkljačić, Diana; Pavlović, Nikola; Šupraha Goreta, Sandra; Kobasić, Ivana; Lovrenčić-Huzjan, Arijana; Bašić Kes, Vanja

Citirajte ovaj rad

Margetić, S., Ćelap, I., Delić Brkljačić, D., Pavlović, N., Šupraha Goreta, S., Kobasić, I. ... Bašić Kes, V. (2020). Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations. Biochemia Medica, 30. (1), 74-82. doi: 10.11613/BM.2020.010702

Margetić, Sandra, et al. "Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations." Biochemia Medica, vol. 30, br. 1, 2020, str. 74-82. https://doi.org/10.11613/BM.2020.010702

Margetić, Sandra, Ivana Ćelap, Diana Delić Brkljačić, Nikola Pavlović, Sandra Šupraha Goreta, Ivana Kobasić, Arijana Lovrenčić Huzjan i Vanja Bašić Kes. "Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations." Biochemia Medica 30, br. 1 (2020): 74-82. https://doi.org/10.11613/BM.2020.010702

Margetić, S., et al. (2020) 'Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations', Biochemia Medica, 30(1), str. 74-82. doi: 10.11613/BM.2020.010702

Margetić S, Ćelap I, Delić Brkljačić D, Pavlović N, Šupraha Goreta S, Kobasić I, i sur.. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations. Biochemia Medica [Internet]. 2020. [pristupljeno 12.11.2024.];30(1):74-82. doi: 10.11613/BM.2020.010702

S. Margetić, et al., "Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations", Biochemia Medica, vol. 30, br. 1, str. 74-82, 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:163:734731. [Citirano: 12.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:163:734731
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
AutorSandra Margetić
AutorIvana Ćelap
AutorDiana Delić Brkljačić
AutorNikola Pavlović
AutorSandra Šupraha Goreta
AutorIvana Kobasić
AutorArijana Lovrenčić-Huzjan
AutorVanja Bašić Kes
Autorova ustanovaSveučilište u Zagrebu
Farmaceutsko-biokemijski fakultet
(Zavod za biokemiju i molekularnu biologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Farmacija
Medicinska biokemija
Sažetak (engleski)
Introduction: Clinical application of rivaroxaban and apixaban does not require therapeutic monitoring. Commercial anti-activated factor X (anti-FXa) inhibition methods for all anti-FXa drugs are based on the same principle, so there are attempts to evaluate potential clinical application of heparin-calibrated anti-FXa assay as an alternative method for direct FXa inhibitors. We aimed to evaluate relationship between anti-FXa methods calibrated with low molecular weight heparin (LMWH) and with drug specific calibrators, and to determine whether commercial LMWH anti-FXa assay can be used to exclude the presence of clinically relevant concentrations of rivaroxaban and apixaban. Materials and methods: Low molecular weight heparin calibrated reagent (Siemens Healthineers, Marburg, Germany) was used for anti-FXa activity measurement. Innovance heparin (Siemens Healthineers, Marburg, Germany) calibrated with rivaroxaban and apixaban calibrators (Hyphen BioMed, Neuville-sur-Oise, France) was used for quantitative determination of FXa inhibitors. Results: Analysis showed good agreement between LMWH calibrated and rivaroxaban calibrated activity (κ = 0.76) and very good agreement with apixaban calibrated anti-Xa activity (κ = 0.82), respectively. Low molecular weight heparin anti-FXa activity cut-off values of 0.05 IU/mL and 0.1 IU/mL are suitable for excluding the presence of clinically relevant concentrations (< 30 ng/mL) of rivaroxaban and apixaban, respectively. Concentrations above 300 ng/mL exceeded upper measurement range for LMWH anti-FXa assay and cannot be determined by this method. Conclusion: Low molecular weight heparin anti-FXa assay can be used in emergency clinical conditions for ruling out the presence of clinically relevant concentrations of rivaroxaban and apixaban. However, use of LMWH anti-FXa assay is not appropriate for their quantitative determination as an interchangeable method.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBiochemia Medica
Brojčani podacivol. 30, br. 1, str. 74-82
p-ISSN1330-0962
e-ISSN1846-7482
DOIhttps://doi.org/10.11613/BM.2020.010702
URN:NBNurn:nbn:hr:163:734731
Datum objave publikacije2020
URL dokumentahttps://hrcak.srce.hr/234052
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2020-04-09 14:41:05